Copyright © 2004 Published by Elsevier B.V.
Anticoagulant and antithrombotic activities of a chemically sulfated galactoglucomannan obtained from the lichen Cladonia ibitipocae
Received 31 March 2004;
References and further reading may be available for this article. To view references and further reading you must purchase this article.
Abstract
A galactoglucomannan (GGM), isolated from the lichen Cladonia ibitipocae, consisted of a (1 → 6)-linked main chain of α-mannopyranose units, substituted by α- and β-d-galacto (α- and β-d-Galp)-, β-d-gluco (β-d-Glcp) - and α-d-mannopyranosyl (α-d-Manp) groups, and was sulfated giving a sulfated polysaccharide (GGM-SO4) with 42.2% sulfate corresponding to a degree of substitution of 1.29. NMR studies indicated that after sulfation, the OH-6 groups of galactopyranosyl and mannopyranosyl units were preferentially substituted. GGM-SO4 was investigated in terms of its in vitro anticoagulant and in vivo antithrombotic properties. Those of the former were evaluated by its activated partial thromboplastin (APTT) and thrombin time (TT), using pooled normal human plasma, and compared with that of 140 USP units mg−1 for a porcine intestinal mucosa heparin. Anticoagulant activity was detected in GGM-SO4, but not in GGM. The in vivo antithrombotic properties of GGM-SO4 were evaluated using a stasis thrombosis model in Wistar rats, intravenous administration of 2 mg kg−1 body weight totally inhibiting thrombus formation. It caused dose-dependent increases in tail transection bleeding time. The results obtained showed that this sulfated polysaccharides is a promising anticoagulant and antithrombotic agent.
Keywords: Anticoagulant activity; Sulfated polysaccharide; Galactoglucomannan
Article Outline
- 1. Introduction
- 2. Experimental
- 2.1. Materials
- 2.2. Isolation of galactoglucomannan and its sulfation
- 2.3. NMR spectroscopy
- 2.4. Methylation analysis
- 2.5. Clotting assay
- 2.6. Animals
- 2.7. Stasis-induced venous thrombosis model
- 2.8. Tail transection bleeding time
- 2.9. Statistics
- 3. Results
- 3.1. Sulfation of the galactoglucomannan
- 3.2. Methylation analysis of GGM-SO4
- 3.3. Anticoagulant activity of GGM-SO4
- 3.4. Stasis-induced venous thrombosis model
- 3.5. Tail transection bleeding time
- 4. Discussion
- 5. Conclusion
- Acknowledgements
- References







E-mail Article
Add to my Quick Links

Cited By in Scopus (7)

40 IU/mg), which is mainly mediated by thrombin inhibition by heparin cofactor II. It also accelerates thrombin and factor Xa inhibition by antithrombin but at a lower potency. Sulfated fucan from 




